Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Trends in overleving bij uitgezaaid melanoom: analyse 2013-2021
apr 2024 | Dermato-oncologie